Abstract 807P
Background
Ovarian cancer (OC) is the most lethal gynecologic tumor and is characterized by a widespread metastasis in abdominal cavity. Accurate preoperative evaluation is important for the specification of surgical procedures and prediction of surgical outcomes.Currently, a variety of imaging techniques can be used for preoperative evaluation of ovarian cancer such as the Computed Tomography (CT) Suidan score. However, the Magnetic resonance imaging (MRI) based preoperative evaluation was not fully explored. Here, our study explores the feasibility of MRI as a preoperative assessment in OC patients.
Methods
This is a prospective, non-randomized, single-center trial of 134 epithelial ovarian cancer (EOC) patients treated with surgical cytoreduction between 2018 and 2022. All patients underwent preoperative MRI scan. The imaging score consists of lesion size scores in 33 areas of the abdominal cavity.
Results
Complete cytoreduction (CC) was achieved in 81 (60.4%) of 134 patients. CC patients with a median MRI score of 10(4 - 44) and the median MRI score of patients who were incompletely cytoreduced (IC) was 15(5 - 48). By comparing imaging scores with those seen in surgery, we found that MRI evaluation is in good agreement with intraoperative observation. However, for areas such as the small bowel mesentery, the MRI score is lower than the intraoperative score, while for lymph node metastases the MRI score is higher than the intraoperative score. Through multi-factor analysis, we have screened clinical and imaging criteria related to IC including CA125 level, prognostic nutritional index (PNI), diaphragmatic surface of spleen lesion, gallbladder fossa lesion and small bowel mesentery lesion. Based on these criteria, we have constructed preoperative imaging scores and the ‘predictive score’ was assigned to each criterion based on its multivariate OR.
Conclusions
Our research explores the feasibility of incorporating tumor load into MRI based preoperative assessment for OC patients. Also, we identified 5 criteria associated with IC, and developed a predictive model which may be helpful in treatment planning.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
789P - Real-world (RW) duration of treatment in first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC): CHAR1ZMA study
Presenter: Floor Backes
Session: Poster session 11
790P - Uniform prospective molecular analysis of endometrial carcinoma: Feasibility, outcomes, and effect on management
Presenter: Bradley Corr
Session: Poster session 11
791P - Development and validation of nomograms to predict survival in patients with high-grade serous ovarian cancer
Presenter: Xiaolian Peng
Session: Poster session 11
792P - Prognostic role of the modeled CA-125 KELIM in early FIGO stage I and II ovarian cancers (OC): A GCIG individual-patient data meta-analysis
Presenter: Pauline Corbaux
Session: Poster session 11
793P - Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)
Presenter: Ana Maria Catana
Session: Poster session 11
794P - Efficacy of gemcitabine (gem) based therapy in ovarian clear cell carcinoma (OCCC)
Presenter: Jerold Loh
Session: Poster session 11
795P - Tolerability and effectiveness of niraparib in long-term responders with platinum-sensitive recurrent ovarian cancer (GEICO-88R study)
Presenter: Juan Cueva Banuelos
Session: Poster session 11
796P - Initial management and long-term outcome of advanced low-grade serous ovarian cancer (LGSOC) exploring role of surgery and maintenance therapy in the French multicentre ESME database
Presenter: Thomas Papazyan
Session: Poster session 11
797P - Impact of consolidation cycles in predicting recurrence in patients treated with EMA-CO for high-risk gestational trophoblastic neoplasia
Presenter: Antoine DELEUZE
Session: Poster session 11
798P - Survival analysis of non-metastatic gestational choriocarcinoma (NMGCC) patients treated with chemotherapy
Presenter: Sakhr Alshwayyat
Session: Poster session 11